Anna Maria Cafro
Overview
Explore the profile of Anna Maria Cafro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martino E, Pitino A, Offidani M, Pepa R, Gozzetti A, Bongarzoni V, et al.
Haematologica
. 2025 Mar;
PMID: 40045883
Not available.
2.
Martino E, Derudas D, Rossi E, Stefanoni P, Mangiacavalli S, Zamagni E, et al.
Hematol Oncol
. 2025 Feb;
43(2):e70042.
PMID: 39898517
This multicenter real-world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara-R). The majority were under...
3.
Martino E, Derudas D, Rossi E, Terlizzi S, Reddiconto G, Stefanoni P, et al.
Haematologica
. 2024 Nov;
PMID: 39605207
Not available.
4.
Cavallaro G, Paris L, Stefanoni P, Pavoni C, Mangiacavalli S, Cartia C, et al.
Mediterr J Hematol Infect Dis
. 2024 Jun;
16(1):e2024049.
PMID: 38882460
No abstract available.
5.
Furlan A, Cea M, Pavan L, Galli M, Clissa C, Mangiacavalli S, et al.
Cancer Med
. 2024 Apr;
13(7):e7071.
PMID: 38558233
Introduction: Ixazomib, lenalidomide, and dexamethasone (IRd) have been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the TOURMALINE-MM1. Objectives And Methods: We conducted a...
6.
Cantoni S, Galitzia A, Mancini V, Cafro A, Cairoli R
EJHaem
. 2024 Feb;
5(1):260-261.
PMID: 38406505
No abstract available.
7.
Zappaterra A, Civettini I, Cafro A, Pezzetti L, Pierini S, Anghilieri M, et al.
Blood Transfus
. 2024 Feb;
22(4):328-337.
PMID: 38315530
Background: Induction with daratumumab-based regimens followed by autologous stem cell transplantation is the current standard for newly diagnosed multiple myeloma (NDMM) patients eligible for intensive chemotherapy. However, concerns emerged regarding...
8.
Raab M, Cohen Y, Schjesvold F, Aardalen K, Oka A, Spencer A, et al.
Leukemia
. 2023 Apr;
37(6):1349-1360.
PMID: 37024520
B-cell maturation antigen (BCMA) is an ideal target in multiple myeloma (MM) due to highly specific expression in malignant plasma cells. BCMA-directed therapies including antibody drug conjugates, chimeric antigen receptor-T...
9.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci M, Dimopoulos M, et al.
Lancet Haematol
. 2020 May;
7(6):e456-e468.
PMID: 32359506
Background: The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma....
10.
Montefusco V, Corso A, Galli M, Ardoino I, Pezzatti S, Carniti C, et al.
Br J Haematol
. 2020 Jan;
188(6):907-917.
PMID: 31898319
Bortezomib- and lenalidomide-containing regimens are well-established therapies in multiple myeloma (MM). However, despite their extensive use, head-to-head comparisons have never been performed. Therefore, we compared bortezomib and lenalidomide in fixed-duration...